3 recruiting, 1 not yet recruiting. 4 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Recruiting 3, Not yet recruiting 1 |
| Phase 3 | 1 | Not yet recruiting 1 |
Follow VEXAS syndrome: new trials by email Literature Review of VEXAS syndrome trials Research Report on VEXAS syndrome
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A 52-Week Study Evaluating the Efficacy and Safety of Arumakimig (MAS825) in Participants With VEXAS Followed by Open-Label Extension (OLE) Period Arumakimig, Placebo, Oral glucocorticoids - VEXAS Syndrome | Phase 2 | Recruiting | Novartis Pharmaceuticals | 120 | 2026-10-30 | 2026-10-13 |
| A Study Evaluating the Efficacy and Safety of Momelotinib in Participants With Vacuoles, E1-enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) Syndrome Momelotinib, Glucocorticoids, Placebo - VEXAS Syndrome | Phase 2 / Phase 3 | Not yet recruiting | GlaxoSmithKline | 136 | 2026-08-05 | 2026-06-01 |
| Momelotinib in VEXAS Syndrome Momelotinib treatment - VEXAS Syndome, Myelo Dysplastic Syndrome | Phase 2 | Recruiting | Groupe Francophone des Myelodysplasies | 57 | 2025-11-25 | 2026-08-10 |
| A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS) Pacritinib, Placebo - VEXAS, VEXAS Syndrome | Phase 2 | Recruiting | Swedish Orphan Biovitrum | 156 | 2025-05-28 | 2026-10-16 |
Myelodysplastic Syndromes (2) · Arthralgia (1) · Arthritis (1) · Hematologic Neoplasms (1)
Bone Marrow Diseases (2) · Hematologic Diseases (2) · Hemic and Lymphatic Diseases (2) · Joint Diseases (1) · Musculoskeletal Diseases (1) · Neoplasms (1) · Neoplasms by Site (1) · Neurologic Manifestations (1) · Pain (1) · Pathological Conditions, Signs and Symptoms (1) · Signs and Symptoms (1)
Glucocorticoids (2) · 11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (1) · N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide (1)
GlaxoSmithKline (1) · Groupe Francophone des Myelodysplasies (1) · Novartis Pharmaceuticals (1) · Swedish Orphan Biovitrum (1)
France (2) · Japan (2) · Canada (1) · Germany (1) · Italy (1) · Spain (1) · United Kingdom (1) · United States (1)
2025 (1)